Journal of Law and Health
Volume 29

Issue 2

Note

12-31-2016

Mending Invisible Wounds: The Efficacy and Legality of MDMAAssisted Psychotherapy in United States' Veterans Suffering with
Post-Traumatic Stress Disorder
Jonathan Perry
Cleveland-Marshall College of Law

Follow this and additional works at: https://engagedscholarship.csuohio.edu/jlh
Part of the Food and Drug Law Commons, Health Law and Policy Commons, Medical Jurisprudence
Commons, Medicine and Health Commons, Mental Disorders Commons, and the Substance Abuse and
Addiction Commons

How does access to this work benefit you? Let us know!
Recommended Citation
Jonathan Perry, Mending Invisible Wounds: The Efficacy and Legality of MDMA-Assisted Psychotherapy in
United States' Veterans Suffering with Post-Traumatic Stress Disorder, 29 J.L. & Health 272 (2016)
available at https://engagedscholarship.csuohio.edu/jlh/vol29/iss2/9

This Note is brought to you for free and open access by the Journals at EngagedScholarship@CSU. It has been
accepted for inclusion in Journal of Law and Health by an authorized editor of EngagedScholarship@CSU. For
more information, please contact library.es@csuohio.edu.

MENDING INVISIBLE WOUNDS: THE EFFICACY
AND LEGALITY OF MDMA-ASSISTED
PSYCHOTHERAPY IN UNITED STATES’
VETERANS SUFFERING WITH POST-TRAUMATIC
STRESS DISORDER
JONATHAN PERRY*

I. INTRODUCTION ............................................................................ 273
II. BACKGROUND ............................................................................ 276
A. Brief History of MDMA: Origins, Therapeutic Uses, and
Cultural Impact. .................................................................. 276
B. Public Opposition, the Controlled Substances Act, and the
Grinspoon Case .................................................................. 279
III. ACCEPTED MEDICAL USE OF MDMA TO TREAT POST-TRAUMATIC
STRESS DISORDER IN VETERANS ..................................................... 284
A. Accepted Medical Use Defined ...................................... 284
B. DEA Findings and Rationale in Scheduling MDMA...... 285
C. MDMA’s Accepted Medical Use in the Context of
Medically Assisted Psychotherapy...................................... 287
IV. APPLYING THE CHEVRON STANDARD TO DRUG ENFORCEMENT
AGENCY SCHEDULING ..................................................................... 292
A. The First Circuit Correctly Concludes that Director Lawn’s
Findings Were Not Arbitrary and Capricious .................... 293
B. The First Circuit Incorrectly Concludes that the Director’s
Conclusions were Sufficient under the “Substantial Evidence”
Standard .............................................................................. 295
V. MDMA IN SCHEDULE III ........................................................... 297
A. Meeting the Schedule III Criteria .................................. 297
B. Impact of Schedule III Classification of MDMA Treatment
in Veterans Suffering with PTSD ........................................ 300
VI. CONCLUSION ............................................................................. 300

272

2016]

MENDING INVISIBLE WOUNDS

273

I. INTRODUCTION
In 2001, the United States invaded Afghanistan.1 Two years later, American armed
forces were fully deployed in both Afghanistan and Iraq, and their presence persists to
this day.2 Amidst the loss of life exists a subtler tragedy: psychiatrists report that
around 20% of service members suffer from post-traumatic stress disorder upon
returning home from combat.3 More distressingly, an average of 22 veterans commit
suicide each day.4
Though anecdotal, the story of Andrew Brennan provides an extreme but powerful
narrative of PTSD’s suffocating grasp on returning veterans.5 The State of Alabama
recently refused to stay the execution of the 66-year-old Vietnam veteran who was
imprisoned for shooting an Atlanta police officer in 1998.6 At trial, Mr. Brennan’s
lawyers pointed out that he had been diagnosed with severe posttraumatic stress
disorder as a result of his service in Vietnam. 7 On the night of the shooting, Mr.
Brennan was “in the throes of an emotional flashback” when he pulled a rifle from his
truck and began shooting at the officer.8 At the time of the tragedy, Mr. Brennan had
been prescribed anti-psychotic medication for a diagnosed bipolar disorder.9 This
approach—a reliance solely on prescription medication as a remedy for PTSD—
proved unsuccessful here, as it has so many times before. 10
Although many of organizations exist to support troops suffering with posttraumatic stress disorder,11 a veteran’s ability to receive effective emerging treatments
from their healthcare provider is frustrated by outdated legislation. 12 Emerging

* Jonathan Perry J.D. Cleveland-Marshall College of Law, 2016.
1 BARBARA SALAZAR TORREON, CONGRESSIONAL REPORT SERVICE, U.S. PERIODS OF WAR
(2010).
2

Id.

3

See Lisa Richardson et al., Prevalence Estimates of Combat-Related PTSD: A Critical
Review, 44 AUSTRALIAN AND NEW ZEALAND J. OF PSYCHIATRY 4 (2011).
4 See JANET KEMP AND RONALD BOSSARTE, DEP’T OF VETERAN AFFAIRS, SUICIDE REPORT:
2012 (2013).
5 Panel Refuses to Stop Execution of Vietnam Vet With PTSD, MIL. TIMES (January 13,
2015).
6

Id.

7

Id.

8

Id.

9

Id.

10

See, e.g. Disjunctive Risperidone Treatment for Antidepressant-Resistant Symptoms of
Chronic Military Service–Related PTSD, 306 J. of Am. Med. Ass’n 5 (2011).
11

Id.

12 See Justin Smith, The Values and Control of MDMA, 10 CONTEMP. JUSTICE REV. 297
(2007).
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treatments and research seeking to combat PTSD are hindered by the Drug
Enforcement Agency’s (“DEA”) interpretation, and subsequent reinterpretations, of
the Controlled Substances Act.13 Scheduling substances as “Schedule I” prohibits
healthcare professionals from utilizing emerging remedies in PTSD treatment by
erecting various administrative and bureaucratic barriers to research. 14 As a result,
some substances with positive medical purposes are kept from those who must be
afforded all possible remedies.15
Schedule I classification requires medical researchers to obtain FDA approval
before experimentation, a burdensome hurdle in the way of furthering understanding
of the substance.16 Researchers are further required to record and secure all testing
procedures in conformance with DEA guidelines, a process that further confines the
scope of research.17 Lastly, classifying drugs as Schedule I has historically created a
stigma that makes research vastly more difficult, as volunteers become scarce and the
incentive to investigate becomes associated with criminal behavior and a poor
professional reputation. 18 The timing of the classification strikes a massive blow to
the mental stability of returning troops; neurological and psychopharmacological
research began providing its most insightful and promising research just as the federal
government began crippling access to the substance. As a result, a massive pool of
veterans, ranging from Vietnam to the current engagement, were stripped of a chance
to alleviate the vicious symptoms of post-traumatic stress disorder.
The most compelling emerging treatment is commonly referred to as “MDMAassisted psychotherapy,” in which psychiatrists incorporate 3,4-methylenedioxymethamphetamine into one-on-one or group therapy sessions with veterans suffering
with PTSD.19 Although psychiatrists studied the therapeutic benefits of MDMAassisted psychotherapy throughout the 1970’s and 1980’s, research was suppressed by
the DEA’s classification of MDMA as a Schedule I substance in 1986. 20 In the last
decade, however, there has been a resurgence of interest, funding, and medical
13

Id.

14

Id.

15

See Alan Zarembo, Exploring Therapeutic Effects of MDMA on Post-Traumatic stress,
L.A. TIMES, (March 15, 2014), http://articles.latimes.com/2014/mar/15/local/la-me-mdma20140316.
16 Grinspoon v. Drug Enforcement Admin., 828 F.2d 881, 896 (1st Cir. 1987). “Dr.
Grinspoon has correctly identified several ways in which the placement of MDMA in Schedule
I will impede his research and the efforts of other researchers interested in exploring the
possibility of clinical uses for MDMA.” Id.
17

Id.

18 Renee Lewis, DEA approves study using MDMA for anxiety in seriously ill patients, Al
Jazeera America (March 17, 2015), http://america.aljazeera.com/articles/2015/3/17/clinicaltrial-approved-for-mdma-psychotherapy.html .
19 MDMA-assisted therapy sessions demonstrated the greatest efficacy when conducted
two-three times annually. See Michael Mithoefer ET AL., Safety and Efficacy of±3, 4methylenedioxymethamphetamine-Assisted Psychotherapy in Subjects with Cronic, TreatmentResistant Posttraumatic Stress Disorder, 25 J. OF PSYCHOPHARMACOLOGY 439 (2011).
20 See NAT’L INSTITUTE OF HEALTH, WHAT WE KNOW AND DON’T KNOW ABOUT MDMA: A
SCIENTIFIC REVIEW (2001).
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research on the efficacy, safety, and necessity of MDMA-assisted therapy.21 This
comes as a result of the current state of veteran treatment effectiveness, which cannot
suppress the growing prevalence of the disorder.22
Though Veteran Affairs has provided crucial life sustaining—and often
lifesaving—treatments to returning soldiers, the substantial and ever-increasing rates
of veteran suicides, drug addictions, and criminal behavior indicate a need for broader
options in treatment.23 One of the most profound discoveries uncovered through
MDMA-assisted psychotherapy research is MDMA’s facilitation of the alleviation of
addictive behavior in subjects, and, as a result, an alleviation of addictions in
general.24 Addiction is one of the key symptoms of posttraumatic stress disorder, and
drug abuse plays a large role in the other afflictions suffered by veterans, namely
criminal activity and a high rate of suicide. 25 If there is any hope of treating this
debilitating psychotic phenomenon—or at least containing its rapid growth and
addressing its profound depth—alternative remedies as a means must not be ignored
for a normative end.26
Accordingly, this article will argue that physicians must be able to treat PTSD
victims through MDMA-assisted psychotherapy, an alternative remedy to PTSD
treatment that has shown overwhelming promise in domestic and international
medical research. In doing so, it will first discuss 21 U.S.C.A. § 812, which labels
MDMA as a Schedule I substance and prohibits healthcare professionals from using
MDMA-assisted psychotherapy to treat PTSD victims.27 Next, the article will assert
that the Drug Enforcement Agency (“DEA”) erroneously categorized MDMA as a
substance lacking an accepted medical use and lack of safety under medical
supervision.28 The article will set out studies, domestic and international, where
clinical testing of MDMA-assisted therapy to treat PTSD have been met with
21 Treating
PTSD
with
http://www.mdmaptsd.org/news.html.
22 See Cukor
(2009).

ET AL.,

MDMA-Assisted

Psychotherapy

website:

Emerging treatments for PTSD, 29 CLIN. PSYCHOLOGY REV. 715

23

Jack Gilbert, Veterans are being given MDMA to help them forget about war, Vice News
(April 22, 2014, 1:00 PM) https://news.vice.com/article/veterans-are-being-given-mdma-tohelp-them-forget-about-war.
24 See Maia Szalavitz, Ecstasy as Therapy: have some of its negative effects been
overblown?, Time (Feb. 18, 2011) http://healthland.time.com/2011/02/18/ecstasy-as-therapyhave-some-of-its-negative-effects-been-overblown/; See also Moreno-Lopez, et. al., Neural
Correlates of the Severity of Cocaine, Heroin, Alcohol, MDMA and Cannabis Use in
Polysubstance Abusers: A Resting-PET Brain Metabolism Study, PLOS One (June 29, 2012).
25 See Tanielian & Jaycox, Invisible Wounds of War: psychological and cognitive injuries,
their consequences, and services to assist recover, RAND Center for Military Policy Research
(2008).
26

See Brian Anderson, The agony of ecstasy: the quiet mission to fight PTSD with MDMA,
Vice News (August 16, 2011) http://motherboard.vice.com/blog/the-agony-and-the-ecstasythe-quiet-mission-to-fight-ptsd-with-psychedelic-drugs; see also John Richards, Amphetamine
derivatives, 5 Nova Science 81 (2006).
27

Controlled Substances Act, 21 U.S.C. § 812 (2009).

28

Id.
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overwhelmingly positive results. Finally, the article will argue that MDMA’s
accepted medical use, low physical and psychological dependence, and known safety
under medical supervision support its classification as a Schedule III under the CSA,
and that the 1986 classification of MDMA as a Schedule I narcotic was, and continues
to be, an arbitrary and capricious agency interpretation of an otherwise viable piece of
congressional legislation.
II. BACKGROUND
A. Brief History of MDMA: Origins, Therapeutic Uses, and Cultural Impact.
In 1914, the German pharmaceutical company Merck & Co. patented the substance
3, 4-methylenedioxymethamphetamine, commonly known as MDMA. 29 The origins
of its synthesis are unclear: some assert that the purpose behind Merck’s patent was
to create an anorectic or diet suppressant, while others suggest that Merck utilized
MDMA as a precursor to hydrastinine, a haemostatic drug. 30 Some evidence suggests
that both American and German researchers resynthesized MDMA in the 1950s while
seeking to create stimulants for Air Force pilots, however this fact is also contested.31
The first officially documented experiments involving MDMA in the United States
occurred in a U.S. military-sponsored animal study in 1953.32 The results of the study
remained classified until 1972.33 In this study, researchers investigated the lethal
dosage levels (“LDs” or “LD/50s”) of mescaline and seven analogs in five separate
species of mammals: mice, rats, dogs, guinea pigs, and monkeys.34 The core purpose
of the study was to identify a lethal dosage of the substances in mammals.35 For
obvious ethical reasons, however, the lethal dosage levels in humans could only be
inferred.36
In 1965, Alexander Shulgin, a chemist working at Dow Pharmaceutical Company,
resynthesized MDMA.37 Shulgin then published the first study testing MDMA’s

29

See A.C. Parrott, Human Pharmacology of Ecstasy: A Review of 15 Years of Empirical
Research, 16 HUMAN PSYCHOPHARMACOLOGY: CLINICAL AND EXPERIMENTAL 557 (2001).
30 Bernschneider-Reif, et al., The origin of MDMA (“Ecstasy”) – separating the facts from
the myth (2006).
31

Id.

32

Id.

33

See Hardman et al., Relationship of the structure of mescaline and seven analogs to
toxicity and behavior in five species of laboratory animals, 25 Toxicology and Applied
Pharmacology 299 (1972).
34

See Alexander Shulgin, History of MDMA, in ECSTASY: CLINICAL, PHARMACOLOGICAL
1, 1-20 (1990).

AND NEUROLOGICAL EFFECTS OF THE DRUG MDMA
35

Hardman, supra note 33.

36

Id.

37

See Shulgin, supra note 34.
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psychotropic effects in human subjects.38 This study compared the effects of MDMA,
3,4-Methylenedioxyamphetamine (“MDA”), and 2-(5-Methoxy-1H-indol-3yl)ethanamine (“mexamine”) on human subjects.39 Shulgin’s study concluded that
MDMA had a higher threshold than MDA,40 and further that the substance
“appear[ed] to evoke an easily controlled altered state of consciousness with emotional
and sensual overtones. It can be compared…to psilocybin, devoid of the hallucinatory
component, or to low levels of MDA.” 41 Additionally, Shulgin acknowledged a need
for further acute studies of psychotropics in human subjects, specifically in regards to
MDMA’s potential effect on mental illness.42
Two years later, researchers investigated MDMA’s pharmacological properties in
humans.43 In 1978, Dr. George Greer published a clinical study whereby
experimenters administered MDMA in humans. 44 Greer administered low level of
MDMA to 29 patients in a medical setting. 45 The test sought to curtail “drug abuse
problems, facilitate communication and intimacy between people involved in emotion
relationships, and…as an adjunct to insight-oriented psychotherapy.”46 The test
produced some undesirable side effects, none of which were serious and none that
lasted longer than a week.47 These included increased blood pressure and heart rate
over the span of two hours.48 Desirable side effects included alleviation of symptoms
in subjects with DSM-III psychological disorders, “relieving low self-esteem and
increasing self-acceptance and self-confidence,” and relief of physical ailments such
as back pain.49
Around the same time, researchers throughout the United States began
administering MDMA in the therapeutic setting, recording its physical and
psychological effects on human patients suffering with psychological disorders.50
Undesirable physical effects, identical to those identified in Dr. Greer’s 1976 study,

38 See Alexander Shulgin & Nichols, D.E., Characterization of Three New Psychomimetics,
74 PSYCHOPHARMACOLOGY OF HALLUCINOGENS 83 (1978).
39

See Shulgin, supra note 34. MDA came into the view of medical researchers for its
potential in treating various symptoms of Parkinson’s disease. Id.
40

Id.

41

Id.

42

See Shulgin, supra note 38.

43

See Shulgin, supra note 38.

44 See e.g., George Greer, MDMA: A New Psychotropic Compound and Its Effects in
Humans (1983).
45

Id.

46

See Shulgin, supra note 38.

47

See Greer, supra note 44.

48

Id.

49

Id.

50 See Philip Wolfson, Meeting at the Edge with Adam: a Man for All Seasons, 18 J. OF
PSYCHOACTIVE DRUGS 329 (1986).
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were uniformly reported.51 These included elevated heart rate and blood pressure, as
well as the suppression of appetite.52 No instances of death, injury, or long-term
neurological deficiency were reported.53
Subjectively, volunteers identified strong improvements in “self-understanding,”
spiritual and personal growth, a lessening of an otherwise powerful desire to abuse
drugs or alcohol, and a renewed drive to address personal issues.54 Other accounts
indicate an increased desire and capacity to suppress drug abuse, heightened
sensations of self-worth, and a transcendent sense of calm that persisted well beyond
the conclusion of the experiments. 55 MDMA’s significant psychological effects on
patients suffering with depression, drug or alcohol abuse, and sexual dysfunction
prompted a worldwide interest in the medical benefits of MDMA in the early 1970’s56
Following early research, the general consensus in the medical community was
that “MDMA is reasonably safe, produces positive mood changes in users, does not
cause negative problems if used sparingly and episodically, and is without evidence
of abuse.”57 That being said, the scientific data through the 1970’s and early 80’s had
yet to conclusively show that MDMA use did not produce long-term neurotoxicity.58
Nonetheless, as one study concluded, “MDMA, at the doses tested, has remarkably
consistent and predictable psychological effects that are transient and free of
clinically-apparent major toxicity.”59
As its medical and social popularity increased throughout the 1970’s and early
1980’s, the Health and Human Services Department urged the continuation and
expansion of MDMA research.60 In spite of this, the FDA refrained from permitting
any Investigational New Drug (“IND”) license to medical researchers seeking to
research MDMA, thus hindering the potential for expanded clinical research in
humans.61 With the medical community’s desire for greater MDMA research came

51 See Harold Kalant, Pharmacology and Toxicology of “Ecstasy” and Related Drugs, 165
CANADIAN MED. J. 917, 925 (2001); see also Sotiria Bexis & James Docherty, Effects of MDMA,
MDA and MDEA on Blood Pressure, Heart Rate, Locomotor Activity and Body Temperature in
the Rat Involve α-Adrenoceptors, 147 J. OF PHARMACOLOGY, 926 (2006).
52

See Shulgin, supra note 38.

53

Id.

54 George Greer & Requa Tolbert, Subjective Reports of the Effects of MDMA in a Clinical
Setting, 18 J. OF PSYCHOACTIVE DRUGS 319 (1986).
55 Marsha Rosenbaum & Rick Doblin, Why MDMA Should Not Have Been Made Illegal, in
THE DRUG LEGALIZATION DEBATE (James A. Inciardi ed., 1991).
56

See Shulgin, supra note 38.

57

Joseph Downing, The psychological and physiological effects of MDMA on Normal
Volunteers (1986).
58

Id.

59

Id.

60

See id.

61

Id.
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public controversy and subsequent Congressional legislation, acting in conjunction to
bring “clinical studies with MDMA…to a complete halt.”62
B. Public Opposition, the Controlled Substances Act, and the Grinspoon Case
As scientific knowledge of MDMA’s benefits began to grow, so too did its
reputation as a dangerous “mind-altering psychedelic.”63 In 1981, the countercultural
publication Wet ran a story promoting the use of MDMA. 64 The publication caused
great controversy, and initiated a steeply divided debate on the medical benefits,
harms, and legality of MDMA.65
By 1983, MDMA had grown popular in the American south. 66 In Texas, for
example, several night clubs and bars were known to distribute MDMA to patrons.67
The popularity of the substance among young club-goers attracted the attention of
cocaine dealers, who began organizing complex and far-reaching sale structures of
MDMA. As a result, “distribution grew and recreational, as opposed to the more
therapeutically oriented use, increased dramatically. 68
A few months later, open sales in Texas prompted legislators to push scheduling
of MDMA. Shortly thereafter, the DEA filed its Notice of Proposed Rulemaking to
the Federal Register, “announcing its intention to place MDMA in Schedule I.”69 As
legislators and federal officials began their march toward full-force illegalization,
medical professionals mobilized in resistance to this possibility. A “small but
dedicated group of medical professionals maintained that MDMA was too valuable in
therapy” to merely dismiss it.70 Other medical researchers, however, along with the
U.S Department of Justice, raised concerns of abuse and potential neurotoxicity in
humans.71
As MDMA gained medical and cultural popularity in the 1970’s and throughout
the early 1980’s, researchers quickly began to focus on what it perceived to be
“potential neurotoxic qualities.”72 The Food and Drug Administration (FDA)
62

Id.

63

See Shulgin, supra note 38.

64 See generally Ecstasy: Everything Looks Wonderful When You’re Young and On Drugs,
WET MAGAZINE, p. 76 (1981).
65

See Shulgin, supra note 38.

66

How the Starck Club Changed Dallas, D Magazine (2013).

67

Rosenbaum, supra note 55.

68

Id.

69 Marshal Rosenbaum and Rick Doblin, Why MDMA Should Not Have Been Made Illegal,
THE PSYCHEDELIC LIBRARY, http://www.psychedelic-library.org/rosenbaum.htm (last visited
March 24, 2016).

See Shulgin, supra note 34.
71 See
id.; see also E. O’Hearn et al., Methylenedioxyamphetamine and
Methylenedioxymethamphetamine Cause Selective Ablation of Serotonergic Axon Terminals in
Forebrain, THE J. OF NEUROSCIENCE, 2788, 2800 (1988).
72

Id.
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“temporarily scheduled” the drug as a dangerous narcotic in 1985, refusing to approve
it for interstate marketing approval.73
In its 1987 Notice of Proposed Rulemaking, the DEA asserted that MDMA “lacked
any legitimate medical uses, significantly threatened the health of users, and had a
high potential for abuse.”74 In response, medical professionals with experience in
conducting MDMA-assisted therapy throughout the United States fiercely opposed
the “unjustified” agency determination.75 These doctors asserted that MDMA was a
“tremendous aid” to alleviating the symptoms of several devastating psychiatric
conditions, and sought to support that assertion data. 76
In spite of strong opposition from the medical community, DEA director John
Lawn held an emergency scheduling hearing, where he announced that MDMA was
an “immanent hazard to public safety,” and placed it under Schedule I.77 In response,
Dr. Lester Grinspoon, a professor of Psychiatry at Harvard University, brought suit
against the DEA administrator.78 Dr. Grinspoon won his case before the Second
Circuit Court of Appeals because, as the Second Circuit stated, “FDA approval is not
determinative of a lack of acceptable medical use.”79 Thus, the scheduling was
remanded to the DEA director for reconsideration.80 Three months later, however,
the DEA reissued its ruling, and once again classified MDMA as a schedule I narcotic
with no accepted medical use.81
On March 23, 1988 the DEA placed MDMA into Schedule I under the Controlled
Substances Act (“CSA”) The CSA, which Congress passed in 1970, set out to
accomplish three main goals: (1) to prevent drug abuse and dependence; (2) provide
treatment and rehabilitation for drug abusers and dependents; and (3) strengthen law
enforcement in the context of drug abuse. 82 The CSA created five classifications for

73

See Greer & Tolbert, supra note 44.

74

21 U.S.C. § 812 (2009).

75 See 53 FR 5156-01 (1988). Schedules of Controlled Substances; Scheduling of 3,4Methylenedioxymethamphetamine (MDMA) Into Schedule I of the Controlled Substances Act,
53 Fed. Reg. 5156 (February 22, 1988)(to be codified at 21 CFR pt 1308).
76

Id.

The New York Times, U.S. Will Ban ‘Ecstasy,’ A Hallucinogenic Drug,
http://www.nytimes.com/1985/06/01/us/us-will-ban-ecstasy-a-hallucinogenic-drug.html (last
visited March 24, 2016).
77

78

Grinspoon v. Drug Enf’t Admin., 828 F.2d 881, 882 (1 st Cir. 1987).

79

Id.

80 Richard Glen Boire, The Politics of Medicine: the Schedluing of MDMA, CENTER FOR
COGNITIVE LIBERTY & ETHICS, http://www.cognitiveliberty.org/dll/mdma_scheduling_
history.htm (last visited March 24, 2016).
81

Id.

82

Comprehensive Drug Abuse Prevention and Control Act of 1970, Pub. L. No. 91-513, 84
Stat. 1236 (1970).
Sec. 101. The Congress makes the following findings and
declarations:
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varying substances based on the drug’s potential for abuse, dependence, and accepted
medical uses.83 In a final scheduling hearing, Director Lawn concluded that pursuant
to the purposes of the CSA, and due to a lack of an accepted medical use and lack of
known safety under medical supervision, MDMA would hereinafter be classified as a
Schedule I.84
C. Veteran PTSD, Current Treatments, and MDMA-Assisted Psychotherapy85

(1) Many of the drugs included within this title have a useful and legitimate medical
purpose and are necessary to maintain the health and general welfare of the American
people. Id.
83 United
States Drug Enforcement Administration (DEA), Drug Scheduling,
http://www.dea.gov/druginfo/ds.shtml (last visited March 24, 2016) .; Schedule I substances are
those considered to have a high potential for abuse, no accepted medical use, and a lack of
accepted safe use under medical supervision. Id.
84 Schedules
of
Controlled
Substances;
Scheduling
of
3,4Methylenedioxymethamphetamine (MDMA) Into Schedule I of the Controlled Substances Act,
supra note 76.; Remand, 53 Fed.Reg. 5156 (1988).

a) Establishment
There are established five schedules of controlled substances, to be known as schedules
I, II, III, IV, and V. Such schedules shall initially consist of the substances listed in this
section. The schedules established by this section shall be updated and republished on
a semiannual basis during the two-year period beginning one year after October 27,
1970, and shall be updated and republished on an annual basis thereafter.
(b) Placement on schedules; findings required
Except where control is required by United States obligations under an international
treaty, convention, or protocol, in effect on October 27, 1970, and except in the case of
an immediate precursor, a drug or other substance may not be placed in any schedule
unless the findings required for such schedule are made with respect to such drug or
other substance. The findings required for each of the schedules are as follows:
(1) Schedule I-(A) The drug or other substance has a high potential for abuse.
(B) The drug or other substance has no currently accepted medical use in treatment in
the United States.
(C) There is a lack of accepted safety for use of the drug or other substance under
medical supervision.
(2) Schedule II-(A) The drug or other substance has a high potential for abuse.
(B) The drug or other substance has a currently accepted medical use in treatment in the
United States or a currently accepted medical use with severe restrictions.
85 The DEA has recently permitted a study of MDMA for patients suffering with anxiety
due to life threatening illnesses. “The height of the drug war in 1985, the agency classified
MDMA in Schedule I under the Controlled Substances Act. The federal government considers
Schedule I drugs to be among the "most dangerous," with no known medical benefits and the
potential for "severe psychological or physical dependence." That decision overruled a previous
recommendation by the DEA's chief administrative law judge that the drug be placed in
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This scheduling placed severe restrictions on MDMA research. For example, for
several decades the FDA refused to permit experimentation because of a “concern for
the health of volunteers.”86 Further, therapists and physicians abandoned clinical use
and research of MDMA in fear of losing their license and damaging their
reputations.87 Thus, a substance with a substantial record of therapeutic benefits was
abandoned as a result of the DEA’s ruling.
Today, post-traumatic stress disorder is a highly prevalent psychological disorder
in veterans of war.88 The symptoms of PTSD are numerous and severe. These
include vivid flashbacks, hallucinations, insomnia, nightmares, hyperarousal, negative
changes in beliefs or mood, and other drastic behavioral changes. 89 These symptoms
can be crippling to veterans seeking to assimilate to civilian life.90
For example, Tim Amoroso is a 24-year-old ex-Army Ranger who fought in
Afghanistan.91 Upon returning home to New Hampshire, Tim battled with “memories
of looking for body parts” as a result of experiencing a suicide bomb attack on his
platoon.92 Like hundreds of thousands of returning vets, Tim turned to the VA in an
attempt to eradicate these vicious memories. 93
The VA prescribed Tim with antidepressants and antianxiety medications, neither
of which brought meaningful relief.94 The lack of efficacy of these medications led
Tim to seek alternative remedies to treat his PTSD.95 One summer, Tim purchased
MDMA and ingested it under the supervision of a friend. 96 According to Tim, the
positive effect of the MDMA outweighed anything he had experienced on

Schedule III, which would have allowed doctors to continue using it in therapy.” See Wing,
infra note 170.
86 Constance
Scharff, Ph.D., Does MDMA Have Psychotherapeutic Potential,
http://www.constancescharff.com/?p=248 (last visited March 24, 2016).
87

Marsha Rosenbaum and Rick Doblin, supra note 55.

88 Veterans and PTSD,
Veterans statistics: PTSD, Depression, TBI, Suicide,
http://www.veteransandptsd.com/index.html (last visited March 24, 2016)
89

U.S. Department of Veterans Affairs, PTSD: National Center for PTSD,
http://www.ptsd.va.gov/public/PTSD-overview/basics/symptoms_of_ptsd.asp (last visited
March 24, 2016).
90

Id.

91 Alan Zarembo, Exploring Therapeutic Effects of MDMA on Post-Traumatic Stress
Disorder, L.A. TIMES, (March 15, 2014), http://articles.latimes.com/2014/mar/15/local/la-memdma-20140316.
92

See id.

93

Id.

94

Id.

95

Id.

96

Id.
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antidepressants.97 “I feel like I found meaning again,” said Tim. “My life wasn’t as
bad as I thought it was.”98
Since 2001, over 1.5 million American soldiers like Tim have been deployed to
Afghanistan or Iraq.99 Upon returning from deployment, Veteran Affairs estimates
that 20-30% of soldiers suffer from post-traumatic stress disorder, major depressive
disorder, traumatic brain injury, or some combination of the three.100 Until recently,
the hidden nature of these wounds has hindered research and subsequent
understanding of this mental disorder.101
All Operation Iraqi Freedom (“OIF”) and Operation Enduring Freedom (“OEF”)
veterans are eligible to receive aid from the VA. 102 That being said, young veterans
face several challenges in accessing quality mental treatment from the VA.103 For
example, the VA operates on a fixed budget, and cannot be expected to keep pace with
the rapid amount of OIF/OED and Vietnam veterans seeking treatment. 104 Further,
VA services may give higher priority to physically-disabled veterans. Also, many
veterans do not live close to a VA facility. 105
Additionally, current PTSD treatments have not been met with meaningful
success.106 The VA offers four different services for PTSD treatment: one-on-one
mental health assessment and testing, medications, individual and family
psychotherapy, and group therapy. 107 Regardless of the available treatments, the
average PTSD victim still qualifies for the disease four months after treatment. 108
Psychiatrists, physicians, and medical researchers question the efficacy of Prozac,

97

Id.

98

Id.

99

RAND Center for Military Health Policy Research, Invisible Wounds: Mental Health and
Cognitive Care Needs of America’s Returning Veterans (2008), http://www.rand.org/
content/dam/rand/pubs/research_briefs/2008/RAND_RB9336.pdf .
100

Id.

101

Id.

102 U.S. Department of Veterans Affairs, Returning Service Members (OEF/OIF/OND),
http://www.oefoif.va.gov/healthcare.asp (last visited March 25, 2016).
103

RAND Center for Military Health Policy Research, supra note 99, at 4.
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Id.

105

Id.
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Id.

107 U.S. Department of Veteran Affairs, PTSD Treatment Programs in the U.S. Department
of Veteran Affairs, http://www.ptsd.va.gov/public/treatment/therapy-med/va-ptsd-treatmentprograms.asp (last visited March 25, 2016).
108 C. Bartley Frueh & Sally Satel, Veterans Affairs Needs to Get a Clue About PTSD
Treatment, TIME (June 27, 2014), http://time.com/2933356/ptsd-awareness-day-veteransaffairs-treatment/ .
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Paxil, and Zoloft in treating PTSD symptoms.109 Furthermore, research suggests that
antidepressants are often no more effective than a placebo in treating veterans who
suffer with PTSD.110 Ineffective treatments and the common practice of selfmedication undoubtedly aggravate the fragile mental state of veterans with the
disorder.111 In an effort to address this growing problem, the FDA recently approved
a study of MDMA-assisted psychotherapy in treating veterans, police officers, and
firefighters who suffer with PTSD.112 Since MDMA remains in Schedule I, however,
psychiatrists may not conduct MDMA-assisted therapy sessions on an as-needed
basis, and access for veterans is limited to these types of seldom-approved volunteer
studies.113
III. ACCEPTED MEDICAL USE OF MDMA TO TREAT POST-TRAUMATIC STRESS
DISORDER IN VETERANS
A. Accepted Medical Use Defined
Schedule I substances are those that the DEA determines lack an accepted
medical use, have a high potential for abuse, and cannot be used safely under medical
supervision.114 The CSA does not define “accepted medical use” in the definition
section of the act.115 Thus, its meaning has been the subject of much debate since the
act’s promulgation.116
There are two main inquiries the DEA will undertake in determining whether a
substance has an accepted medical use. First, the DEA considers five distinct factors

109

Zoloft, for example, has been found to be effective in female patients, but not in male.
Michael A. Hertzberg, M.D., et al., Lack of Efficacy for Fluoxetine in PTSD: A Placebo
Controlled Trial in Combat Veterans, 12 ANNALS OF CLINICAL PSYCHIATRY 101 (2000).
110 Jay C. Fournier, M.A., et al., Antidepressant Drug effects and Depression Severity: A
Patient-Level Meta-Analysis, 303 JOURNAL OF AM. MED. ASS’N 47 (2009).
111

See Alexander McFarlane, Epidemiological Evidence About the Relationship Between
PTSD and Alcohol Abuse, 23 ADDICTIVE BEHAVIORS 813 (1998); see also Paige Ouimette, et
al., Course and Treatment of Patients with Both Substance Use and Posttraumatic Stress
Disorders, 23 ADDICTIVE BEHAVIORS 785 (1998).
112 Michael
C. Mithoefer, et al., The safety and efficacy of ±3,4methylenedioxymethamphetamine-assisted psychotherapy in subjects with chronic, treatmentresistant posttraumatic stress disorder: the first randomized controlled pilot study, 25 J. OF
PSYCHOPHARMACOLOGY 439 (2010). Drug Policy Alliance, Healing a Broken System: Veterans
and the War on Drugs (November 2012), http://www.drugpolicy.org/sites/default/
files/DPA_Healing%20a%20Broken%20System_Veterans%20and%20the%20War%20on%2
0Drugs_November%202012_Final_0.pdf .
113

Id.

114

21 U.S.C. § 812 (2009).

115

Marijuana Scheduling Petition, 57 Fed. Reg.10,499, 10,504 (March 26, 1992). (stating
regrettably, the Controlled Substances Act does not speak directly to what is meant by ‘currently
accepted medical use).
116

Id., at 10,503.
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of the substance. Second, the DEA considers whether the substance has FDA
approval.117
The DEA will consider the following five factors to determine whether a substance
has an accepted medical use in the United States: (1) the substance’s chemistry is
known and reproducible; (2) there are adequate safety studies; (3) there are adequate
and well controlled studies determining efficacy; (4) the drug is accepted by qualified
experts; and (5) the scientific evidence is widely available. 118 The DEA will conclude
that a substance has an accepted medical use if all five of these factors are met.119
B. DEA Findings and Rationale in Scheduling MDMA
In order to determine the DEA’s rationale for placing MDMA in Schedule I,
an analysis of its 1988 final ruling is required. In that ruling, Director Lawn
extrapolated upon each of the five enumerated factors, ultimately concluding that
MDMA deserved Schedule I classification.120
First, the administrator noted that MDMA lacked FDA approval. Director Lawn
relied upon the fact that a single FDA pharmacologist, “experienced in evaluating the
safety and efficacy of drugs,” found that current research provided “no data or
evidence to support a claim that MDMA is effective as a therapeutic agent.”121
Nonetheless, Director Lawn correctly indicated that fact that a drug is not lawfully
approved for marketing is a “factor to be considered in determining whether a
substance lacks accepted safety for use under medical supervision, but is not
conclusive.”122
He further noted that MDMA had not been subject to sufficient animal testing to
support trials in humans, stating that the “published literature contains no references
117 Denial of Petition To Initiate Proceedings To Reschedule Marijuana, 76 Fed. Reg. 40,552,
40,559 (July 8, 2011)(to be codified at 21 CFR pt. 2).
118

See 76 Fed. Reg. 40552 (2011); See id. For the DEA to find that a substance has a
currently accepted medical use under the CSA, all five factors must be met. 76 Fed. Reg. 40552
(2011); All. for Cannabis Therapeutics v. Drug Enf’t Admin., 15 F.3d 1131, 1134 (1994). “The
current test dates back to a 1992 order denying NORML's 1973 rescheduling petition. In
announcing the test, DEA Administrator Robert C. Bonner explained that it was derived from
the Food, Drug and Cosmetic Act. Bonner “[t]he pattern of initial scheduling of drugs in the
Controlled Substances Act, viewed in light of the prior legal status of these drugs under the
FDCA, convinces me that Congress equated the term ‘currently accepted medical use in
treatment in the United States’ as used in the Controlled Substances Act with the core FDCA
standards for acceptance of drugs for medical use.” Denial of Petition to Initiate Proceedings
To Reschedule Marijuana, supra note 118. Importantly, however, Bonner cautioned that “not
… every FDCA requirement … is pertinent to scheduling determinations under the Controlled
Substances Act,” so it appears to be possible for a drug that does not have FDA approval to be
found to have a currently accepted medical use under the DEA's test. Marijuana Scheduling
Petition, supra note 116, at 10,506.” Id.
119

Marijuana Scheduling Petition, supra note 115, at 40,552.

120

Schedules
of
Controlled
Substances;
Scheduling
of
3,4Methylenedioxymethamphetamine (MDMA) Into Schedule I of the Controlled Substances Act,
supra note 76, at 5156.
121

See 53 FR 5156-01 (1988). Id., at 5157.
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Id., at 5158.
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to the clinical use of MDMA nor animal studies to indicate such clinical use.”123
Without clinical studies, the Director asserted that all information regarding long term
neurotoxicity in humans is mere speculation, and thus that there was no way of
knowing whether it was safe.124 Director Lawn explained the safety concern as
follows:
Studies in animals [show] that MDMA produces long term serotonergic
nerve terminal degeneration. Such effects would not necessarily be
observed immediately in individuals who had taken the drug. The long term
safety of MDMA has not been established through reproductive or
carcinogenic studies. Since MDMA has not been shown to be effective for
treating a specific condition, it is impossible to make a risk/benefit analysis
of the drug. Two psychiatrists who testified on behalf of the agency in the
proceedings indicated that they would not administer MDMA to humans
until and unless further studies had been conducted to establish its safety
and lack of neurotoxicity.125
Additionally, the Director observed that no data presented at the hearing had the
potential for peer review, and that the evidence available was “purely anecdotal.”126
He noted that the evidence in the record before the DEA merely demonstrated that a
few psychiatrists had administered MDMA to approximately 200 subjects.127 “These
physicians were not conducting scientific studies with MDMA, they were
administering the drug as if it was an approved product which had been scientifically
tested.”128 Thus, he concluded that the evidence presented was anecdotal accounts
and not “scientific” so as to demonstrate an accepted medical use. 129
Further, he asserted that MDMA lacked any “therapeutic use,” citing a “panel of
international experts” who allegedly arrived at the same conclusion. 130 Thus, the
director concluded that the published scientific and medical literature as of 1988,
coupled with information from the files of the Food and Drug Administration (i.e. a
lack of interstate marketing approval), “did not establish or support claims of
123 Id. The director concluded that “[t]he published literature contains no references to the
clinical use of MDMA nor animal studies to indicate such a clinical use. Recognized texts,
reference books and pharmacopeia contain no references to the therapeutic use of MDMA. The
two unpublished studies supporting the therapeutic use of MDMA which were presented during
the hearings, do not contain any data which can be assessed by scientific review to draw a
conclusion that MDMA has a therapeutic use. Indeed, the psychiatrists who conducted the
studies admit that the information which they obtained was anecdotal, and that the studies were
not scientifically controlled.” Id.
124

Id.

125

Id.

126

Id.

127

Id.

128

Id.

129

Id.

130 Lastly, Mr. Lawn noted that the lack of FDA interstate marketing approval “clearly
demonstrates” an absence of an accepted medical use for MDMA. Id.
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therapeutic use of MDMA, as an adjunct to psychotherapy, in treatment in the United
States.”131 Accordingly, Director Lawn concluded that MDMA had no accepted
medical use and deserved Schedule I status. 132
Today, pure MDMA has been proved to be “sufficiently safe” when ingested a
minimal number of time over a long period.133 MDMA-assisted psychotherapy
follows this trajectory, as MDMA ingestion occurs once during a three-month
period.134 Additionally, further animal testing has provided a foundation for MDMA
testing in humans.135 Recent studies have been successfully completed in the medical
setting, demonstrating a plausibly degree of certainty toward the safety of the tests. 136
Evidence is not purely anecdotal; the sample sizes in modern experiments range from
12-60 human test subjects, and the scope of MDMA research spans the globe.137
Finally, Director Lawn fails to indicate the rationale of the “panel of international
experts,” or what, if any, evidentiary basis they provided for their conclusion. 138 On
the contrary, the evidence today demonstrates a greater international interest in curing
PTSD through MDMA-assisted psychotherapy than our national interest.
C. MDMA’s Accepted Medical Use in the Context of Medically Assisted
Psychotherapy
First, MDMA’s chemistry is known and reproducible today.139 According to the
DEA, a substance’s chemistry is known and reproducible when it can be reproduced
into dosages which can be standardized.140 This standard is elucidated by several
hearings regarding the accepted medical use of marijuana.141 For example, in
concluding that the chemistry of marijuana is not known or reproducible, the DEA
reasoned that “over 400 different chemicals have been identified in the plant,” and that
131

Id.

132

Id.

133 Students for Sensible Drug Policy, SSDP Psychedelic Legalization Toolkit,
http://ssdp.org/campaigns/ssdp-psychedelic-legalization-toolkit/ (last visited March 25, 2016).
134

MAPS, Treating PTSD with MDMA-Assisted
mdmaptsd.org/patients.html (last visited March 25, 2016).

Psychotherapy,

http://www.

135 National
Institute on Drug Abuse, The Neurobiology of Ecstasy,
https://www.drugabuse.gov/publications/teaching-packets/neurobiology-ecstasy (last visited
March 25, 2016).
136
137
138

See MAPS – MDMA-Assisted Psychotherapy, http://www.maps.org/research/mdma.
Id.
See 53 FR 5156-01 (1988).

139 Harold Kalant, Pharmacology and Toxicology of “Ecstasy” (MDMA) and Related Drugs,
165 CANADIAN MED. ASS’N J. 917, 925 (2001); James Rochester, Ecstasy (3,4
Methylenedioxymethamphetamine): History, Neurochemistry, and Toxicology, 12 AM. BOARD
FAM PRAC. 137, 137 (1999).
140 Marijuana Scheduling Petition; Denial of Petition; Remand, 57 Fed. Reg. 10499, 10504
(Mar. 26, 1992).
141

Id.
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“proportions of concentrations differ from plant to plant, depending on growing
conditions, age of the plant, harvesting and storage factors.” 142
Unlike marijuana, the chemical structure and function of MDMA does not depend
on external conditions, nor is it composed of a significant amount of varying
chemicals.143
These four chemicals combine to synthesize MDMA in its pure
form.144 Ecstasy, the illicit street drug which utilizes PMK to produce a psychoactive
effect, includes a much higher amount of chemicals and adulterous additives. 145
Accordingly, the chemical structure of pure MDMA is well known, and is easily
reproducible in a clinical setting and in comparison with marijuana or other Schedule
I substances.146
Second, medical researchers around the world have conducted a significant
amount of studies regarding MDMA’s safety. 147 As stated by the DEA in 1992, “there
must be adequate studies, by all methods reasonably applicable, to show the
pharmacological and toxicological effects of the drug” in order to know its safety. 148
These include animal studies and clinical tests with large number of humans.149 The
studies “need not be well controlled, but must be adequate.” 150
A profusion of studies testing the effects of MDMA on animal subjects has
occurred since the 1950’s.151 In 1986, researches at the Medical College of Virginia
tested the self-administration of MDMA in rhesus monkeys. 152 In 2001, Johns
Hopkins University tested the cognitive performance of MDMA-treated rhesus

142

Id. at 10507

143

MDMA, specifically 3,4-Methylenedioxy-N-Methylamphetamine, is the sole
psychoactive agent in the chemical, and contains no other chemicals that produce the
psychoactive effect. There are four “principle precursors” used in the manufacture of MDMA:
safrole, isosafrole, piperonal, and 3,4-methylenedioxyphenyl-2-propanone (“PMK”).
Alexander Shulgin, The Background and Chemistry of MDMA, 18 J. OF PSYCHOACTIVE DRUGS
291, 291 (1986).
144

Id.
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Id.
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Id.
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Id.
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Grinspoon, 828 F.2d at 881.

149

Id. at 894-95.

150

Edison Pharmaceuticals Co. v. FDA, 600 F.2d 831, 840 (D.C. Cir. 1979).

151 The first known test occurred in 1953 at the University of Michigan. The United States
Military conducted tests on a variety of species in an attempt to determine neurotoxicity animals
in a variety of animals. Lethal dosages of MDMA were find at high concentration in rats, mice,
and monkeys. See Shulgin, supra note 34
152 Patrick Beardsley, et al., Self-Administration of Methylenedioxymethamphetamine
(MDMA) by Rhesus Monkeys, 18 DRUG AND ALCOHOL DEPENDENCE 149, 149 (1986).
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monkeys.153 A study of primate PET-scans before and after administration of a
neurotoxic level of MDMA revealed its effect on serotonin in the primate brain. 154
The lethal dosage level of MDMA has not been determined in humans.
Nonetheless, researchers have conducted many clinical tests on a significant number
of human subjects.155 In 1978, clinical psychiatrist Alexander Shulgin administered
MDMA to fellow therapists in an uncontrolled study of the subjective effects of
MDMA.156 Shulgin noted the physiological effects on heart rate and body
temperature, as well as its mood elevated and spiritual qualities.157 No toxic qualities
in humans were identified or recorded.158
In 1994, the National Institute of Health conducted a study on the neurotoxicity of
MDMA in the human brain. 159 The NIH study measured the neurotoxic effects of
MDMA against physical characteristics of subjects, such as weight, height, sex, and
personality traits.160 The test concluded that MDMA users had “lower scores on
personality measures of impulsivity,” and that MDMA may have an effect on
suppressing aggressive personality states. 161
In July of 2000, the University of Psychiatry in Zurich published a study of the
psychological and physiological effects of MDMA on humans who had been
pretreated with haloperidol, a substance used in treating schizophrenia and other
psychiatric mood disorders.162 The study, which included 14 healthy subjects,
concluded that MDMA produced an “affective state of well-being, with increased
extroversion and socialability.”163 The study noted the physiological effect of
MDMA on healthy individuals, listing an increase in blood pressure and heart rate, as

153

Michael Taffe, et al., Cognitive Performance of MDMA-Treated Rhesus Monkeys:
Sensitivity to Serotonergic Challenge, 27 NEUROPSYCHOPHARMACOLOGY 993, 995-996 (2001).
154 Sudhakar Selvaraj, et al., Brain Serotonin Transporter Binding in Former Users of
MDMA (“ecstasy”), 194 BRIT. J. OF PSYCHIATRY 355, 355 (2009).
155 Charles Grob, MDMA Research: Preliminary Investigations with Human Subjects, 9
INT’L J. OF DRUG POL’Y 119, 121 (1998).
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(2001).
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Toxic Effects of MDMA (ecstasy) on Brain Serotonin Neurons." 358 THE LANCET 1864, 1864
(2001).
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Chronic Post-Traumatic Stress Disorder (PTSD), 27 J. PSYCHOPHARMACOLOGY 40, 40 (2013).
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well as a heightened body temperature. 164 The main complaints from subjects were
fatigue, lack of appetite, and thirst, among others. 165
These studies comprise an adequate foundation through which the safety or danger
of MDMA can be known. A great deal of information regarding the dangers and
benefits of MDMA has been unveiled over the last several decades, especially in
contrast to the medical information available to the scientific community in 1988.
Human clinical testing has demonstrated knowledge of the known risks and benefits
of MDMA.166 These tests demonstrate an adequate safety level that supports an
accepted medical use in the United States.
Third, studies demonstrate the efficacy of MDMA-assisted psychotherapy in
treating soldiers suffering from post-traumatic stress disorder.167 A recent doubleblind study conducted by the Medical University of South Carolina found a 30%
reduction in the Clinically-Administered PTSD Scale (“CAPS”) as compared with
those subjects receiving a placebo.168 Psychiatric researchers in Zurich conducted a
similar study on MDMA-assisted psychotherapy in veterans suffering with PTSD.169
This double-blind study indicated a lessening of PTSD victim CAPS scores after two
months of MDMA-assisted psychotherapy sessions.170 Additionally, the efficacy of
MDMA-assisted PTSD treatment was further analyzed in a 2007 evidence-based
meta-analysis of the treatment.171 A randomized triple-blind comparative study of
MDMA use in conjunction with therapy in firefighters and police officers suffering
with PTSD has been approved by the FDA and is scheduled to occur in 2016. 172
The DEA conclusion that MDMA has “no therapeutic use in the United States” is
no longer scientifically supported.173 In the specific context of the PTSD pandemic
in our nation’s veterans, MDMA-assisted therapy is an effective means to combat
otherwise untreatable symptoms.174

164

Id. at 47.
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Id. at 48.
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Jerrold S Meyer, 3,4-methylenedioxymethamphetamine (MDMA): current perspectives
SUBST ABUSE REHABILITATION 83–99.(2013).
167 U.S. Will Ban ‘Ecstasy,’ A Hallucinogenic Drug, N.Y. TIMES (June 1, 1985),
http://www.nytimes.com/1985/06/01/us/us-will-ban-ecstasy-a-hallucinogenic-drug.html.
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Id.
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A. C. Parrott, The Psychotherapeutic Potential of MDMA (3, 4methylenedioxymethamphetamine): An Evidence-Based Review, 191 PSYCHOPHARMACOLOGY
181, 181 (2007).
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See generally MULTIDISCIPLINARY ASSOCIATION FOR PSYCHEDELIC
SUBSTANCES (June 29, 2010).
173 George Greer, Rebuttal Testimony of George Greer, M.D. in DEA Hearing on Scheduling
of MDMA Under the Controlled Substances Act (last visited May 1, 2016); Grinspoon, 828
F.2d at 891.
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See supra note 85.
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Fourth, the safety and efficacy of MDMA is supported by a community of reliable
medical experts.175 Studies conducted by medical professionals in Zurich have
determined the safety of MDMA-assisted psychotherapy in a clinical setting.176
Psychiatric researchers in the United States have concluded that MDMA-assisted
therapy can be conducted safely and with effective results in PTSD victims. 177 The
FDA has approved a triple-blind study of MDMA-assisted psychotherapy in the
United States, the first of its kind since before it was illegalized in 1986.178 Further,
experiments in Israel and Jordan also provide support for the safety and efficacy of
MDMA-assisted therapy.179
Fifth, the evidence supporting MDMA’s positive effect on post-traumatic stress
disorder is widely available to researchers and the public. In determining whether a
drug is widely available to experts, courts analyze if there is “widely available
scientific literature about the drug,180 “whether it is widely taught in medical
schools181,” and “whether it is widely discussed by experts.” 182
At the time of the original scheduling in 1988, DEA director John Lawn correctly
noted a lack of published literature referencing the clinical use of MDMA. 183 Lawn
pointed to two “unpublished studies supporting therapeutic use of MDMA.” 184
Further, Lawn indicated that recognized texts did not indicate the use of MDMA as a
substance with therapeutic purposes.185
Today, MDMA has fixed itself at the center of academic and medical discussion.
Harvard Medical School plans to study the therapeutic effects of psychedelic
substances on terminally ill patients.186 The FDA approved Harvard University’s
McLean Hospital’s request to reinvigorate research programs incorporating
175

Id.

176

See supra note 112.
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See supra note 134.
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Rick Doblin, Clinical Plan for MDMA (Ecstasy) in the Treatment of Posttraumatic Stress
Disorder(PTSD): Partnering with the FDA, 12 J. PSYCHOACTIVE DRUGS 5, 5 (2002).
180

Premo Pharm. Lab., Inc. v. United States, 629 F.2d 795, 795 (2nd Cir. 1980).
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Lemmon Pharm/ Co. v. Richardson, 319 F. Sup. 375, 378 (E.D. Pa. 1970).
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United States v. Bentex Ulcerine, 469 F. 2d 875, 879-880 (5th Cir. 1972).
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Scheduling of 3,4-Methylenedioxymethamphetamine (MDMA) Into Schedule I of the
Controlled Substances Act; Remand, 53 Fed. Reg. 5156-01 (Feb. 22, 1988). “The published
literature contains no references to the clinical use of MDMA nor animal studies to indicate
such a clinical use. Recognized texts, reference books and pharmacopeia contain no references
to the therapeutic use of MDMA. The two unpublished studies supporting the therapeutic use
of MDMA which were presented during the hearings, do not contain any data which can be
assessed by scientific review to draw a conclusion that MDMA has a therapeutic use.” Id.
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psychedelic medicine.187 Further, the prestigious scientific publication “Scientific
American” has called for the United States to implement MDMA into therapy. 188 The
article correctly indicates that MDMA “had its origin in medical pharmacopeia.”189
The ever-expanding pool of clinical studies and academic discussions , and the surge
in MDMA-assisted psychotherapy studies for PTSD treatment, all indicate a changing
landscape where the effects of MDMA-assisted therapy are widely available to
psychiatrists and researchers in the medical field. 190 Accordingly, in applying these
five factors to the current scientific understand of MDMA, Schedule I classification
must be reconsidered for a schedule that permits healthcare professionals to
adequately address the debilitating symptoms of MDMA.
IV.

APPLYING THE CHEVRON STANDARD TO DRUG ENFORCEMENT AGENCY
SCHEDULING

DEA regulatory action regarding the Schedule I classification can be viewed under
the Chevron “arbitrary and capricious” framework.191
"The power of an
administrative agency to administer a congressionally created . . . program necessarily
requires the formulation of policy and the making of rules to fill any gap left, implicitly
or explicitly, by Congress." 192 If the statute creating a program is ambiguous, that
ambiguity is viewed as an express delegation of legislative discretion to an agency.193
Thus, “regulations are given controlling weight unless they are arbitrary, capricious,
or manifestly contrary to the statute.”194
Having established the ambiguity of the Controlled Substances Act as written by
Congress, the issue of whether MDMA is erroneously scheduled must be viewed
under the “arbitrary, capricious, or manifestly contrary to the statute” framework set
out by the United States Supreme Court in Chevron. 195 This is not exactly an issue of
first impression; the First Circuit dealt with the merits of this exact issue in 1987, in

187 John Horgan, Psychedelic Medicine: Mind Bending, Health Giving, NEW SCIENTIST (Feb.
23, 2005), http://www.newscientist.com/article/mg18524881.400-psychedelic-medicine-mindbending-health-giving.html.
188 Roni Jacobson, Turn On, Tune in, Get Better: Psychedelic Drugs Hold Medical Promise,
SCI. AM. (Sept. 1, 2014), http://www.scientificamerican.com/article/turn-on-tune-in-get-betterpsychedelic-drugs-hold-medical-promise.
189

Id.

190

Id.

191 Grinspoon, 828 F.2d 884; Chevron, U.S.A., Inc. v. NRDC, Inc., 467 U.S. 837, 844 (U.S.
1984), Motor Vehicle Mfrs. Ass'n v. State Farm Mut. Auto. Ins. Co., 463 U.S. 29, 56 (U.S.
1983).
192

Chevron, 467 U.S. at 843 (quoting Morton v. Ruiz, 415 U.S. 199, 231 (1974)).
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the case of Grinspoon v. Drug Enforcement Administration. 196 The court in
Grinspoon analyzed whether the DEA administrator’s conclusion that MDMA had a
high potential for abuse and lacked any accepted medical use was arbitrary and
capricious.197 The court answered both questions in the negative. 198 Nonetheless,
the First Circuit’s conclusion faces seemingly insurmountable challenges when
viewed in relation to the progress of recent MDMA research. 199
A. The First Circuit Correctly Concludes that Director Lawn’s Findings Were Not
Arbitrary and Capricious
Immediately following the DEA’s ruling, psychiatrist and Harvard Medical
Professor Lester Grinspoon petitioned the First Circuit to review Director Lawn’s
classification.200 Dr. Grinspoon asserted four arguments in support of overturning the
DEA ruling. First, Dr. Grinspoon argued that the director misapplied the “accepted
medical uses” standard and thus erroneously found MDMA to be one of the substances
under § 812 that lack an accepted use.201 The final three reasons were premised on
the notion that the scheduling was arbitrary and capricious and therefore must be
vacated.202
Though the First Circuit agreed with Dr. Grinspoon on the first issue, and thus
reversed the judgment and ordered the DEA to reconsider its ruling, Dr. Grinspoon
was unsuccessful in arguing that the DEA interpretation arbitrarily and capriciously
interpreted the CSA.203 The First Circuit concluded that Congress had provided the
DEA with sole power to determine the relative potential for abuse of a substance, so
long as it provided substantial evidence in that regard. 204 Finding that Congress
delegated that authority, and that the conclusion was based on substantial evidence,
the Court refrained from finding the DEA ruling invalid on “arbitrary and capricious”
grounds.205 The Court stated the following:
While we acknowledge that the Administrator's final rule is silent with
respect to the legal standard required for a finding of “high” potential for
abuse, we do not find the Administrator's action to be arbitrary and
capricious. The fourth standard contained in the segment of the Committee
Report quoted above makes it quite clear that the Administrator can
permissibly reach a conclusion regarding a substance's level of potential for
abuse by comparing the substance to drugs already scheduled under the
196

Grinspoon, 828 F.2d at 883.

197

Id.

198

Id.

199

Id.

200

Id.

201

Id. at 884.

202

Id. at 892.

203

Id.

204

Id.

205

Id.

294

JOURNAL OF LAW AND HEALTH

[Vol. 229:273

CSA. Here the Administrator has done just that, offering several findings
concerning the evidence of close structural and pharmacological similarity
between MDMA and other substances, such as MDA,12 which already
*894 have been found to have a high potential for abuse and have been
placed in Schedule I or II.206
Additionally, the Court acknowledged the legislative history of the Controlled
Substances Act.207 The House Committee Report provided that the Administrator can
find a potential for abuse if the following apply:
(1) There is evidence that individuals are taking the drug or drugs
containing such a substance in amounts sufficient to create a hazard to their
health or to the safety of other individuals or of the community; or
(2) There is significant diversion of the drug or drugs containing such a
substance from legitimate drug channels; or
(3) Individuals are taking the drug or drugs containing such a substance on
their own initiative rather than on the basis of medical advice from a
practitioner licensed by law to administer such drugs in the course of his
professional practice; or
(4) The drug or drugs containing such a substance are new drugs so related
in their action to a drug or drugs already listed as having a potential for
abuse to make it likely that the drug will have the same potentiality for
abuse as such drugs, thus making it reasonable to assume that there may be
significant diversions from legitimate channels, significant use contrary to
or without medical advice, or that it has a substantial capability of creating
hazards to the health of the user or to the safety of the community. 208
Here, the court found that the director adhered to the Congressional intent of the
CSA as it pertains to a high potential for abuse. 209 The court stated that the
Administrator “offered several findings concerning the evidence of a close structural
pharmacological similarity between MDMA and MDA, which have already been
found to have a high potential for abuse and have been placed in Schedule I. 210
Further, the Administrator provided “animal studies, human behavioral studies, and a
survey of MDMA users which suggest[ed] that MDMA is related in its effects to
Schedule I substances such as LSD, cocaine, mescaline, and MDA.” 211 The court
concluded that the Administrators approach in analyzing the potential for abuse
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conformed to the intent of Congress, and thus did not render the decision arbitrary and
capricious under the Chevron framework.212
Nonetheless, as demonstrated many studies cited in this article and Dr.
Grinspoon’s arguments before the First Circuit, the question remains as to “whether
the evidence collected by the administrator is sufficient to justify his conclusion that
MDMA has a high potential for abuse.”213
B. The First Circuit Incorrectly Concludes that the Director’s Conclusions were
Sufficient under the “Substantial Evidence” Standard
There is no doubt that the CSA’s legislative history demonstrates Congressional
intent in delegating the “high potential for abuse” determination to the
administrator.214 That being said, the crucial analysis is whether that conclusion can
withstand the notoriously low “substantial evidence” standard. In Am. Textile Mfrs.
Inst. v. Donovan, the Supreme Court held that substantial evidence is that which “such
relevant evidence as a reasonable mind might accept as adequate to support a
conclusion”215 “[E]ven if reasonable minds could also go the other way, we must
uphold the [agency] if its ultimate finding is supported by substantial evidence in the
record as a whole."216
In his original 1986 ruling, Director Lawn cited various scientific studies to
support his conclusion that MDMA had a high potential for abuse. 217 At that time,
Dr. Grinspoon a professor of psychiatry at Harvard University and a medical
researcher, presented his and other professionals studies on the efficacy of MDMA as
212
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213
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Id. “From this, the Administrator draws the proposition that “Congress clearly intended
that the ‘safety and efficacy’ of narcotic and dangerous drugs (e.g., whether such drugs are
acceptable for medical use and safe for such use) be determined by [HHS] under the [FDCA].”
Respondent's Brief at 17–18 (emphasis deleted). The Administrator's conclusion is
objectionable, however, because his parenthetical comment—equating a finding of “safety and
efficacy” by the FDA with a finding of “accepted medical use” and “accepted safety for use ...
under medical supervision”—is totally unsupported by the quoted passage from the House
Committee Report. Nowhere does Congress equate “safety and efficacy” under the FDCA with
the second and third Schedule I criteria contained in section 812(b)(1). This, indeed, is the point
at issue in this litigation, and we are loath to accept such a disingenuous argument.” Id.
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217 “(1) MDMA is the N-methyl analogue of MDA and retains the psychomimetic properties
of MDA; (2) MDMA produces pharmacological effects in common with both central nervous
system ("CNS") stimulants like amphetamine and hallucinogens like MDA in animals; (3)
MDMA and MDA produce the same spectrum of pharmacological effects in mice, dogs, and
monkeys when observed during toxicity studies; (4) MDMA, like MDA, amphetamine, and
methamphetamine, produces neurotoxic effects when administered to animals; (5) MDMA and
MDA may both produce the same neurotoxic effects to serotonergic nerves in humans; (6) in
drug discrimination tests, rats trained to recognize amphetamine also recognized MDA and
MDMA, and rats trained to recognize MDA also recognized MDMA; (7) based on recent tests
involving human subjects, MDMA can be described as maintaining the same potency as MDA,
but exhibiting subtle differences in the qualitative nature of the intoxication.” Grinspoon, supra
note 207at 895.
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an adjunct to therapy.218 Nonetheless, the Court upheld the agency determination that
MDMA had a high potential for abuse, noting that an “appellate court must not
second-guess the particular way the agency chooses to weigh the conflicting evidence
or resolve the dispute.”219
In the event that an agency points to “scientifically respectable evidence” that a
petitioner can “continually dispute with rival, and…equally respectable evidence,” the
court will not question the means by which the agency chooses resolve the dispute.220
Under this framework, substantial evidence must be “scientifically respectable” and,
when a conflict between evidence exists, an agency must resolve that dispute. 221
Director Lawn relied upon evidence in the record that is no longer “scientifically
respectable” as it pertains to our current understanding of the neurotherapuetic effects
of MDMA, especially when viewing within the context of post-traumatic stress
disorder.222 For example, current MDMA research concludes that MDMA lacks the
addictive qualities present in other Schedule I substances like cocaine and heroin. 223
Further, current research shows that MDMA does not cause lead to neurotoxicity
when taken recreationally. One of the largest studies on MDMA, researchers from the
UK concluded that “MDMA use may not result in long-term damage to serotonin
neurons when used recreationally in humans.” 224 Nor is such a finding subject to
conflict, as the studies cited by the Director measure the effect of MDMA when issued
at a threshold level.225
This neurotoxic effect is substantially less than those
frequently identified in heroin and cocaine use.226 MDMA only produces neurotoxic
effects when distributed at its threshold level in nonhuman animals; human studies
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have not produced any of evidence of neurotoxic damage or neurodegeneration
following therapeutic use.227
When looking at the Director Lawn’s rationale in 1986, it becomes apparent that
the medical purposes for which Dr. Grinspoon argued were not met with substantially
conflicting evidence, as the only studies present in the Committee Report contain
studies administering MDMA to animals at threshold, or maximum LD/50 levels, and
not over an extended period of time. Furthermore, a host of scientific data exists
differentiating MDMA’s potential from abuse from other Schedule I substances, with
some studies concluding that MDMA has no potential for abuse whatsoever.
Regardless of a small potential for abuse, it is not high, as required by the CSA, nor is
it at all comparable to substances with which it currently shares Schedule I status.
Nonetheless, DEA scheduling updates and completed lists are reviewed and restated
bi-annually.228 With the growing body of data demonstrating MDMA’s positive
effect on PTSD victims, coupled with the ineffective treatments currently available to
veterans suffering with the disease, there is substantial evidence to support a second
challenge to the rule, and a reversal or reconsideration of Director Lawn’s 1986
classification.
V. MDMA IN SCHEDULE III
A. Meeting the Schedule III Criteria
Schedule III substances are those that the DEA concludes have an accepted
medical use in the United States, a lower potential for abuse than those substances in
Schedule I and II, and low physical dependence or high psychological dependence. 229
Doctors may prescribe Schedule III substances to patients, but the sale or ingestion
without a prescription is illegal.230 Based on the analysis above, MDMA is most
reasonably categorized as a Schedule III substance under the Controlled Substances
Act.231
227
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Under § 812 of the CSA, the “known facts as to MDMA must be compared with
the known facts as to human abuse of other substances.” 232 Consider cocaine, for
example. Cocaine causes a far greater amount of problems in the United States as a
result of its addictive qualities.233 Cocaine produces a high tolerance in users,
produces pleasurable sensations in the brain that incite repetitive use and inevitable
addiction, and is used in a much more consistent way than MDMA.234 Regardless of
these marked differences in abuse prevalence, MDMA and cocaine share Schedule I
classification due to a lack of accepted medical use and high potential for abuse. 235
Aside from MDMA’s social and habitual distinction from cocaine, researchers
have examined MDMA’s potential for abuse in animal studies on rhesus monkeys. 236
Medical researchers have tested many Schedule I, II, and III substances on rhesus
monkeys to determine a potential for abuse by looking at primate rates of selfadministration.237 These tests measure the rate at which monkeys, generally rhesus
monkeys, ingest a particular substance after an initial dosage. 238 Studies of MDMA
indicate that rhesus monkeys self-administer the drug less than other Schedule I
substances, such as cocaine or heroin. 239
Only a small amount of studies have examined MDMA dependence in humans.240
Those studies indicate that ecstasy produces withdrawal symptoms in heavy users. 241
Nonetheless, “craving for ecstasy was low overall,” and social factors, not
physiological responses, incited urges to take MDMA. 242 Thus, “physiological basis
of an ecstasy dependence syndrome might be relatively weaker in comparison to drugs
with clear and marked dependence potential” such as cocaine or other Schedule I
opioids.243
Scientists at the University of Toronto uncovered the acute and long-term effects
of MDMA in average users.244 Acute effects ranged from renewed energy, a sense of
fulfillment, increased sexual arousal, and an overwhelming sense of euphoria, to
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increases in body temperature, heart rate, and a sense of a mental and physical
“crash”.245
Studies of long-term MDMA users shows a prevalence of “serotonin
neurotoxicity.”246 The substantial release of serotonin produced by MDMA intake
causes damage to serotonin metabolites in the cerebrospinal fluid. 247 A long-term
MDMA user releases less serotonin during “neuronal,” or regular activity in brain
activity, has “abnormally low levels of serotonin,” a smaller amount of serotonin
transporter molecules, and altered pattern of blood flow to the brain.” 248
These physical and psychological effects, though significant, do not comport to
the physical and psychological effects of other Schedule I substances.249 For example,
MDA (3,4-Methylenedioxyamphetamine), a structural relative of MDMA, produces
cognitive impairment at low dosage levels and causes hallucinations and
disorientation.250 Physical effects of drugs such as methamphetamine, heroin, and
cocaine far outweigh those produced by MDMA. 251 These drugs are far more
addictive and cause irreparable harm to the human nervous system. 252
Several Schedule III substances share similar qualities with MDMA in the context
of physical dependence. For example, Benzphetamine is an amphetamine that
metabolizes into a methamphetamine upon digestion.253 Benzphetamine suppresses
appetite in order to reduce caloric intake in obese patients. 254
Due to its low potential for abuse and low physical dependence, MDMA
reasonably conforms to the substance characteristics set out in Schedule III. MDMA
possesses a significantly smaller potential for abuse in primate and human subjects
than other Schedule I substances.255 Further, it does not cause a strong physical or
psychological dependence in humans. 256 The physiological effects are relatively
minimum, and the fluctuation of serotonin levels emulate many Schedule III
substances. Accordingly, research today urges Schedule III classification.
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B. Impact of Schedule III Classification of MDMA Treatment in Veterans Suffering
with PTSD
Reclassifying MDMA as a Schedule III substance would provide veterans with an
opportunity to experience the benefits of MDMA-assisted psychotherapy.257 Such a
notion is slowly becoming reality, as the Multidisciplinary Association for
Psychedelic Substances recently completed a Phase 2 Pilot Study of MDMA in
therapy settings.258 The end goal of this study is to acquire approval of MDMA as a
prescription substance by 2021.259 This goal is unattainable in the United States so
long as MDMA remains classified as a substance lacking any accepted medical use.260
In the United States, the FDA has only approved of two pharmacological
treatments for victims of PTSD: Zoloft and Paxil. 261 Zoloft and Paxil act to increase
the amount of serotonin in the brain, utilizing the exact same mechanism as
MDMA.262 MDMA affects serotonin levels “acutely for 4-8 hours,” whereas Zoloft
and Paxil chronically affect serotonin levels and must be taken daily. 263 Thus,
medication not only becomes more burdensome on the patient but more financially
impactful on tight-budgeted organizations like the VA. 264
If MDMA becomes a Schedule III narcotic in the near future, a plethora of
“bureaucratic delays” could be avoided. Research on MDMA’s effect on PTSD would
not be restricted by the necessity of FDA approval; mandatory registration with the
DEA would no longer hinder the once swift and fluid process of research; medical
researchers would not be deterred from furthering their studies because of stringent
DEA reporting guidelines; an inappropriate and unfounded national stigma could be
corrected, and the long road to addressing PTSD could shorten significantly.
VI. CONCLUSION
The justifications for rescheduling MDMA as a Schedule III substance are
plentiful, and as the decade—and the war against posttraumatic stress—continues,
those reasons will continue to present themselves in an irrefutable light. The
understanding of MDMA’s medically accepted use has grown substantially since its
Schedule I classification in 1986.265 Though the stigma against MDMA exists en
masse, its efficacy of a treatment in the limited context of posttraumatic stress disorder
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is piercing societal perception. It is this treatment—an alternative approach to halting
an ever-expanding disorder—that solely justifies a DEA interpretation of the
“medically accepted use” standard. To give MDMA Schedule III status would not
interrupt the Congressional purpose behind the CSA, and would funnel treatment to a
much-needed group of afflicted individuals.
More prevalent than MDMA’s effect on posttraumatic stress disorder is its power
over addiction. Its importance to returning veterans becomes ever the more crucial, as
addiction is one of the strongest, most consistent, and must exacerbating of the
symptoms of PTSD. Again, when viewing MDMA within the context of surrounding
Schedule I narcotics, there is a vast discrepancy in rates of addiction. 266 Further, the
psychedelic—scientifically referred to as hallucinogenic—substances are in that rare
class of Schedule I drugs that have shown positive results insofar as they alleviate
addiction. Thus, a sort of tragic irony exists here, whereby substances deemed as
having a “high potential for abuse” in fact function to curb the abuse of other, more
dangerous Schedule I narcotics.
Physiologically, MDMA acts as a stimulant, increasing heart rate and blood
pressure.267 Accompanying these physical symptoms is a subjective, but uniform
sense of euphoria, love, and compassion, effects that countless of veterans have
reported following MDMA-assisted therapy.268 This is a fundamental change in
perspective that has the opportunity to be incited without forcing veterans to seek
illegal means to that end.269 The efficacy of MDMA-assisted therapy in treating
PTSD has brought MDMA into the international healthcare discussion. The
justifications for keeping it out of the hands of healthcare professionals and patients
far outweigh the physiological and psychological effects of the substance on humans.
Thus, access to MDMA must be provided to veterans if PTSD is to be meaningfully
treated in the near future.
In the last decade, scientific progress has elucidated the power of a stigmatized and
illegalized substance with regard to its effective use in therapy. It is important to note
that the Controlled Substances Act is open for rescheduling hearings on an annual
basis.270 As a result, the DEA will be presented with the opportunity to conform its
legislation to the scientific understand regarding MDMA and its use in psychotherapy,
and will have the opportunity to do so without frustrating congressional purpose. A
rescheduling of the substance to Schedule III, as opposed to Schedule I, would provide
physicians with the ability to administer MDMA in dispersed therapy sessions over a
wide range of time, a technique with proven benefits unseen in the current
antidepressant atmosphere. Making this change will allow outdated drug legislation
to catch up with scientific progress, and in doing so, make a meaningful and necessary
step toward addressing PTSD in American veterans.
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